1. Search Result
Search Result
Results for "

GS

" in MedChemExpress (MCE) Product Catalog:

255

Inhibitors & Agonists

1

Biochemical Assay Reagents

9

Peptides

7

Inhibitory Antibodies

12

Natural
Products

3

Recombinant Proteins

39

Isotope-Labeled Compounds

18

Antibodies

1

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17016
    Oseltamivir phosphate
    45+ Cited Publications

    GS 4104 phosphate

    Influenza Virus Infection Cancer
    Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
    Oseltamivir phosphate
  • HY-104077
    Remdesivir
    Maximum Cited Publications
    214 Publications Verification

    GS-5734

    DNA/RNA Synthesis SARS-CoV Infection
    Remdesivir (GS-5734) is a nucleoside analogue with effective antiviral activity. Remdesivir can inhibit the synthesis of viral DNA or RNA. Remdesivir can be used for the research of infection, such as SARS-CoV and MHV infection .
    Remdesivir
  • HY-103586
    GS-441524
    25+ Cited Publications

    DNA/RNA Synthesis SARS-CoV Infection
    GS-441524 is a potent, orally active and CNS-penetrant viral RNA-dependent RNA polymerase inhibitor. GS-441524 competes with natural nucleosides to block viral RNA transcription as an alternative substrate and RNA chain terminator. GS-441524 inhibits the replication of feline infectious peritonitis virus, African swine fever virus, and severe acute respiratory syndrome coronavirus 2. GS-441524 reduces viral RNA levels in cats. GS-441524 can be used in research related to feline infectious peritonitis, African swine fever, and coronavirus disease 2019 (COVID-19) .
    GS-441524
  • HY-13026
    Idelalisib
    55+ Cited Publications

    CAL-101; GS-1101

    PI3K Autophagy Cancer
    Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.
    Idelalisib
  • HY-16901
    Firsocostat
    20+ Cited Publications

    ND-630; GS-0976; NDI-010976

    Acetyl-CoA Carboxylase Metabolic Disease
    Firsocostat (ND-630; GS-0976; NDI-010976) is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC50 values of 2.1 and 6.1 nM, respectively.
    Firsocostat
  • HY-15232
    Tenofovir alafenamide
    10+ Cited Publications

    GS-7340

    HIV Reverse Transcriptase Infection Cancer
    Tenofovir alafenamide (GS-7340) is an investigational oral proagent of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor.
    Tenofovir alafenamide
  • HY-15005
    Sofosbuvir
    115+ Cited Publications

    GS-7977; PSI-7977

    HCV Infection Cancer
    Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC50 of 92 nM .
    Sofosbuvir
  • HY-13910
    Tenofovir
    5+ Cited Publications

    GS 1278; PMPA

    Reverse Transcriptase HIV HBV Infection Neurological Disease Cancer
    Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV) .
    Tenofovir
  • HY-15602
    Ledipasvir
    30+ Cited Publications

    GS-5885

    HCV SARS-CoV Infection
    Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
    Ledipasvir
  • HY-109083
    Cilofexor
    5+ Cited Publications

    GS-9674

    FXR Autophagy Inflammation/Immunology
    Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research .
    Cilofexor
  • HY-15968
    Entospletinib
    10+ Cited Publications

    GS-9973

    Syk Cancer
    Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with an IC50 of 7.7 nM.
    Entospletinib
  • HY-17605
    Bictegravir
    15+ Cited Publications

    GS-9883

    HIV HIV Integrase Infection
    Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
    Bictegravir
  • HY-12530
    Velpatasvir
    5+ Cited Publications

    GS-5816

    HCV SARS-CoV Infection Inflammation/Immunology Cancer
    Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir
  • HY-126303C
    GS-443902 trisodium
    10+ Cited Publications

    GS-441524 triphosphate trisodium; Remdesivir metabolite trisodium

    DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite Infection
    GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 μM, 5 μM for RSV RdRp and HCV RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734) .
    GS-443902 trisodium
  • HY-109137
    Selgantolimod
    1 Publications Verification

    GS-9688

    Toll-like Receptor (TLR) HBV Infection
    Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection .
    Selgantolimod
  • HY-177080

    GS-1427

    Integrin Inflammation/Immunology
    Emvistegrast (GS-1427) is a quinolone derivative. Emvistegrast is also an inhibitor of α4β7 integrin. Emvistegrast can be used to investigate diseases mediated by α4β7 integrin, such as inflammatory bowel disease .
    Emvistegrast
  • HY-19840

    GS-9857

    HCV Protease Infection Cancer
    Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity . Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with Ki values of 0.038 nM and 0.066 nM, respectively . Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research .
    Voxilaprevir
  • HY-16727
    Presatovir
    5+ Cited Publications

    GS-5806

    RSV Infection
    Presatovir (GS-5806) is an orally bioavailable RSV fusion inhibitor with a mean EC50 value of 0.43 nM .
    Presatovir
  • HY-15601
    Vesatolimod
    10+ Cited Publications

    GS-9620

    Toll-like Receptor (TLR) Apoptosis HBV HCV HIV Inflammation/Immunology
    Vesatolimod (GS-9620) is a potent, selective and orally active agonist of Toll-Like Receptor (TLR7) with an EC50 of 291 nM.
    Vesatolimod
  • HY-15232A
    Tenofovir alafenamide fumarate
    10+ Cited Publications

    GS-7340 fumarate

    HIV Reverse Transcriptase Infection Cancer
    Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral proagent of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor.
    Tenofovir alafenamide fumarate
  • HY-18938
    Selonsertib
    20+ Cited Publications

    GS-4997

    MAP3K Apoptosis Cancer
    Selonsertib (GS-4997), an orally bioavailable, selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC50 of 8.3, has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis.
    Selonsertib
  • HY-12593
    GS967
    5+ Cited Publications

    Sodium Channel Cardiovascular Disease
    GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late INa ) with IC50 values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, respectively.
    GS967
  • HY-109091
    Lanraplenib
    2 Publications Verification

    GS-9876

    Syk Inflammation/Immunology Cancer
    Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
    Lanraplenib
  • HY-100844
    GS-444217
    5+ Cited Publications

    MAP3K Apoptosis Cancer
    GS-444217 is a potent, orally available and selective ATP-competitive inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC50 of 2.87 nM .
    GS-444217
  • HY-110261
    GS143
    2 Publications Verification

    IKK E1/E2/E3 Enzyme NF-κB Inflammation/Immunology
    GS143 is a selec­tive IκBα ubiquitination inhibitor with an IC50 of 5.2 μM for SCF βTrCP1-mediated IκBα ubiquitylation. GS143 sup­presses NF-κB acti­va­tion and tran­scrip­tion of tar­get genes and does not inhibit proteasome activity. GS143 has anti-asthma effect .
    GS143
  • HY-13640

    GS-9219; VDC-1101

    Nucleoside Antimetabolite/Analog Cancer
    Rabacfosadine (GS-9219), a novel proagent of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells.
    Rabacfosadine
  • HY-15232B

    GS-7340 hemifumarate

    HIV Reverse Transcriptase Infection Cancer
    Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an investigational oral proagent of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor.
    Tenofovir alafenamide hemifumarate
  • HY-145119

    SARS-CoV Infection
    GS-621763 is an orally available precursor to GS-441524 that exhibits anti-SARS-CoV-2 viral activity in mice. GS-621763 reduces viral load to undetectable levels in ferrets infected with SARS-CoV-2 .
    GS-621763
  • HY-W394903

    Drug Metabolite JAK Inflammation/Immunology
    GS-829845 is a is a major, active metabolite of Filgotinib (HY-18300). GS-829845 is a JAK1 preferential inhibitor but is approximately 10-fold less potent than the parent and with a longer half-life .
    GS-829845
  • HY-10081
    GS-6201
    1 Publications Verification

    CVT-6883

    Adenosine Receptor Inflammation/Immunology
    GS-6201 (CVT-6883) is a selective adenosine A2B receptor antagonist. GS-6201 displays high affinity and selectivity for the human adenosine A2B receptors (Ki=22 nM) . GS-6201 reduces caspase-1 activity in the heart, and attenuates cardiac remodeling after acute myocardial infarction (AMI) in the mouse . GS-62013 attenuates the airway reactivity induced by NECA, AMP, or allergen in sensitized mice .
    GS-6201
  • HY-137456

    GS-4875

    Ser/Thr Protease Inflammation/Immunology Cancer
    Tilpisertib (GS-4875) is a serine/threonine kinase inhibitor (WO2017007689) .
    Tilpisertib
  • HY-19851

    GS-9131

    Reverse Transcriptase HIV Cancer
    Rovafovir etalafenamide (GS-9131), a proagent of the adenosine nucleotide analogue GS-9148, is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Rovafovir etalafenamide is potent and active against a variety of NRTI mutants, and shows potent anti-HIV-1 activity .
    Rovafovir etalafenamide
  • HY-109091B
    Lanraplenib succinate
    2 Publications Verification

    GS-9876 succinate

    Syk Inflammation/Immunology Cancer
    Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
    Lanraplenib succinate
  • HY-109050
    Alobresib
    2 Publications Verification

    GS-5829

    Epigenetic Reader Domain Cancer
    Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research .
    Alobresib
  • HY-15602A
    Ledipasvir (acetone)
    30+ Cited Publications

    GS-5885 (acetone)

    HCV Infection
    Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
    Ledipasvir (acetone)
  • HY-104077S1

    GS-5734-d4

    DNA/RNA Synthesis Isotope-Labeled Compounds SARS-CoV Infection
    Remdesivir-d4 (GS-5734-d4) is deuterium labeled Remdesivir (HY-104077). Remdesivir (GS-5734) is a nucleoside analogue with effective antiviral activity. Remdesivir can inhibit the synthesis of viral DNA or RNA. Remdesivir can be used for the research of infection, such as SARS-CoV and MHV infection .
    Remdesivir-d4
  • HY-B1826
    Adefovir
    2 Publications Verification

    GS-0393; PMEA

    HBV Reverse Transcriptase Infection
    Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits HBV DNA polymerase. Adefovir has an IC50 of 0.7 μM against HBV in the HepG2.2.15 cell line. Adefovir has good antiviral activity against several viruses, including HBV and herpesviruses .
    Adefovir
  • HY-126303

    GS-441524 triphosphate; Remdesivir metabolite

    DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite Infection
    GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir .
    GS-443902
  • HY-136303
    GS-704277
    3 Publications Verification

    Drug Metabolite Infection
    GS-704277 is an alanine metabolite of Remdesivir (HY-104077). GS-704277 is further hydrolyzed to GA-441524 (HY-103586) with antiviral activity. Remdesivir, a nucleoside analogue with effective antiviral activity, is highly effective in the control of SARS-CoV-2 (COVID-19) infection .
    GS-704277
  • HY-159983

    LPL Receptor Inflammation/Immunology
    GS-2278 is an LPAR1 (lysophosphatidic acid receptor 1) antagonist with potential for research in idiopathic pulmonary fibrosis (IPF) .
    GS-2278
  • HY-147264

    GS-5718

    IRAK Inflammation/Immunology
    Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research .
    Edecesertib
  • HY-114416

    Epigenetic Reader Domain Cancer
    GS-626510 is a potent, and orally active BET family bromodomains inhibitor, with Kd values of 0.59-3.2 nM for BRD2/3/4, with IC50 values of 83 nM and 78 nM foe BD1 and BD2, respectively .
    GS-626510
  • HY-103475

    GABA Receptor Neurological Disease
    GS39783 is a positive allosteric modulator (PAM) of GABABR. Positive modulation of the GABABR can be used for the research of Nicotine addiction .
    GS39783
  • HY-103586A
    GS-441524 hydrochloride
    25+ Cited Publications

    DNA/RNA Synthesis SARS-CoV Infection
    GS-441524 hydrochloride is a potent, orally active and CNS-penetrant viral RNA-dependent RNA polymerase inhibitor. GS-441524 hydrochloride competes with natural nucleosides to block viral RNA transcription as an alternative substrate and RNA chain terminator. GS-441524 hydrochloride inhibits the replication of feline infectious peritonitis virus, African swine fever virus, and severe acute respiratory syndrome coronavirus 2. GS-441524 hydrochloride reduces viral RNA levels in cats. GS-441524 hydrochloride can be used in research related to feline infectious peritonitis, African swine fever, and coronavirus disease 2019 (COVID-19) .
    GS-441524 hydrochloride
  • HY-19842

    CVT 3619

    Adenosine Receptor Cardiovascular Disease Metabolic Disease
    GS-9667 (CVT 3619), a novel N 6-5'-substituted adenosine analog, is a selective, partial agonist of the A1 adenosine receptor (A1AdoR). GS-9667 binds to adipocyte membranes with high (KH=14 nM) and low (KL=5.4 μM) affinities. GS-9667 reduces cyclic AMP content and release of nonesterified fatty acids from epididymal adipocytes with IC50 values of 6 nM and 44 nM, respectively. GS-9667 inhibits lipolysis and has the potential for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA) .
    GS-9667
  • HY-P99841

    AGEN-1423; GS-1423

    CD73 TGF-β Receptor Inflammation/Immunology Cancer
    Dalutrafusp alfa (AGEN-1423; GS-1423) is a specific bifunctional antibody against CD73 and TGF-β, which is involved in the immunosuppressive pathway .
    Dalutrafusp alfa
  • HY-104077S
    Remdesivir-d5
    2 Publications Verification

    GS-5734-d5

    Isotope-Labeled Compounds DNA/RNA Synthesis SARS-CoV Infection
    Remdesivir-d5 (GS-5734-d5) is a deuterium labeled Remdesivir (HY-104077). Remdesivir (GS-5734) is a nucleoside analogue with effective antiviral activity. Remdesivir can inhibit the synthesis of viral DNA or RNA. Remdesivir can be used for the research of infection, such as SARS-CoV and MHV infection .
    Remdesivir-d5
  • HY-120774

    Sodium Channel Cardiovascular Disease
    GS-462808 is an oral active late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with the IC50 of 1.33 μM. GS-462808 can be used for study of arrhythmia .
    GS-462808
  • HY-404046

    Drug Intermediate Others
    GS-1427 intermediate-1 is a key intermediate in the synthesis of GS-1427 (HY-175745) .
    GS-1427 intermediate-1
  • HY-134557

    GSK-3 Cancer
    GS87 is a highly specific and potent GSK3 inhibitor with IC50s of 415nM and 521nM for GSK3α and GSK3β, respectively. GS87 induces differentiation of acute myeloid leukemia (AML) cell lines by effectively activating GSK3-dependent signaling components including MAPK signaling. GS87 modulates key GSK3 target proteins involved in cell proliferation and differentiation more effectively than Lithium and SB415285 (SB). GS87 has the potential for acting as a differentiation agent for non-promyelocytic AML research .
    GS87

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: